Inventor · disambiguated record

Hans-Georg Rammensee

Also filed as: RAMMENSEE HANS G · RAMMENSEE HANS-GEORG

83 granted patents·30 pending applications·745 citations·filing 1992–2025

99Inventor score

Technology areasA61K G01N A61P C07K C12N

Files withIMMATICS BIOTECHNOLOGIES GMBH92 RAMMENSEE HANS GEORG5 UNIV TUEBINGEN MEDIZINISCHE FAKULTAET5 WEINSCHENK TONI5 LUDWIG INST CANCER RES3

Top patents by PatentIndex Score

113 records

0199US11278571B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·8 cites·20 claims
0299US11246889B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·5 cites·20 claims
0399US11071756B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 27, 2021·5 cites·20 claims
0499US10888587B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·8 cites·20 claims
0599US10881690B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 5, 2021·8 cites·20 claims
0699US10869897B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 22, 2020·8 cites·20 claims
0799US10722538B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 28, 2020·8 cites·20 claims
0898US11214608B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 4, 2022·6 cites·20 claims
0998US11078253B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 3, 2021·5 cites·20 claims
1098US11053296B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 6, 2021·5 cites·20 claims
1198US10639332B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
1297US11248035B1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·3 cites·20 claims
1397US10434136B2Powerful MHC-class II peptides derived from survivinIMMATICS BIOTECHNOLOGIES GMBH·Filed 2013·Granted Oct 8, 2019·47 cites·3 claims
1497US9889159B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 13, 2018·16 cites·22 claims
1596US10639331B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
1696US10568909B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 25, 2020·8 cites·20 claims
1796US10463696B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Nov 5, 2019·11 cites·20 claims
1896US10286052B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted May 14, 2019·25 cites·17 claims
1996US10167317B1Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 1, 2019·6 cites·18 claims
2096US9498512B2Powerful MHC-class II peptides derived from survivinRAMMENSEE HANS-GEORG·Filed 2012·Granted Nov 22, 2016·56 cites·5 claims
2196US8647629B2Powerful MHC-class II peptides derived from survivinRAMMENSEE HANS-GEORG·Filed 2009·Granted Feb 11, 2014·56 cites·8 claims
2296US8008431B2Tumor-associated peptides that bind to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2005·Granted Aug 30, 2011·49 cites·19 claims
2395US10144763B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 4, 2018·5 cites·18 claims
2495US10064924B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Sep 4, 2018·24 cites·17 claims
2594US10000533B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Jun 19, 2018·5 cites·4 claims
2694US9023804B2HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereofWEINSCHENK TONI·Filed 2011·Granted May 5, 2015·12 cites·22 claims
2794US7811828B2Method for identifying and quantifying of tumuor-associatedIMMATICS BIOTECHNOLOGIES GMBH·Filed 2005·Granted Oct 12, 2010·34 cites·9 claims
2894US7666984B2Tumour-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2007·Granted Feb 23, 2010·18 cites·2 claims
2993US11957729B2Powerful MHC-class II peptides derived from survivinIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Apr 16, 2024·4 cites·14 claims
3093US8536304B2Tumour-associated peptides that bind to MHC moleculesWEINSCHENK TONI·Filed 2010·Granted Sep 17, 2013·16 cites·10 claims
3193US8399613B2Tumour-associated peptides that bind to MHC moleculesWEINSCHENK TONI·Filed 2010·Granted Mar 19, 2013·15 cites·13 claims
3293US7763711B2Tumour-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2007·Granted Jul 27, 2010·15 cites·12 claims
3392US11819518B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 21, 2023·1 cites·20 claims
3492US10364271B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 30, 2019·2 cites·23 claims
3591US10377797B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·13 cites·25 claims
3691US10196422B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 5, 2019·13 cites·16 claims
3791US7396904B2Tumor-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2004·Granted Jul 8, 2008·25 cites·2 claims
3890US11542303B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
3989US10450346B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·1 cites·20 claims
4089US9783849B2Method for identifying immunoreactive peptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2014·Granted Oct 10, 2017·5 cites·26 claims
4188US8067529B2Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopesRAMMENSEE HANS-GEORG·Filed 2005·Granted Nov 29, 2011·11 cites·17 claims
4287US2024076349A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
4387US2023241107A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4487US2024034769A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
4587US2023201259A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4687US2023241106A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4787US2023086100A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4887US2023312680A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
4987US2023365651A1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
5087US2023285458A1Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites

Showing the top 50 of 113 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Hans-Georg Rammensee files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →